Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 164

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 164
---
1,641,775 
    (50,786 
    (50,786 
          — 
          — 
  1,171,169 
    (38,927 
          — 
   (100,266 
  1,031,976 
   (660,585 
  1,105,291 
    444,706 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |     | 2024 
 2024 | (1,961,815 
    149,637 
    283,712 
   (311,935 
      8,997 
    (23,883 
   (220,796 
   (266,492 
     (2,884 
       (516 
 (2,345,975 
    (41,387 
    (41,387 
  2,005,000 
     74,899 
          — 
          — 
     27,723 
    (88,665 
  2,018,957 
   (368,405 
  2,821,570 
  2,453,165 | ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) 
 ) |
|:---------------------------------------------------------------------------------|:----|:-----------------------------|-----------:|:--|:----|:-----|-----------:|:--|
| Interest expense paid in cash                                                    |     | $                            |        542 |   |     | $    |     23,550 |   |
| Income taxes paid in cash                                                        |     |                              |      8,695 |   |     |      |      3,672 |   |

<div align='center'>The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

| F-5 |

<div align='center'>bioAffinity Technologies, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)</div>

Note 1. NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION

Description of Business

bioAffinity Technologies, Inc., a
Delaware corporation (the “Company,” or “bioAffinity Technologies”), addresses the need for noninvasive diagnosis
of lung cancer at early stage and other diseases of the lung. bioAffinity Technologies’ proprietary platform uses flow cytometry
and automated data analysis built by machine learning, a form of artificial intelligence (“